

SUPPLEMENTARY MATERIAL

Fig. S1A-D. Pre-exercise six-minute ambulation. **A.** Comparing C57BL/6 with *eNOS*-null mice. **B.** Comparing C57BL/6 with *mdx*, *mdx;iNOS*-null, and *mdx;nNOS*-null mice. **C.** Comparing *mdx* with *mdx;Utrn*-null mice. **D.** Comparing C57BL/6 with *mdx* +/- phosphodiesterase 5A inhibitor.

Table S1. Pre-exercise six-minute ambulation data.

Table S2. Post-exercise six-minute ambulation data.

Fig. S1E. Pre- and post-exercise six-minute ambulation assay for *nNOS*-null mice

Fig. S2. Muscle pathology of *mdx;iNOS*-null mice.

Fig. S3. Asymmetric muscle pathology in *mdx* mice.

References for supplemental material.

REFERENCES

- [1] Sena ES, van der Worp HB, Bath PM, Howells DW, Macleod MR. Publication bias in reports of animal stroke studies leads to major overstatement of efficacy. *PLoS Biol.* 2010;8:e1000344.
- [2] van der Worp HB, Howells DW, Sena ES, Porritt MJ, Rewell S, O'Collins V, et al. Can animal models of disease reliably inform human studies? *PLoS Med.* 2010;7:e1000245.
- [3] London AJ, Kimmelman J, Emborg ME. Research ethics. Beyond access vs. protection in trials of innovative therapies. *Science.* 2010;328:829-30.
- [4] Blake DJ, Weir A, Newey SE, Davies KE. Function and genetics of dystrophin and dystrophin-related proteins in muscle. *Physiol Rev.* 2002;82:291-329.